Life-threatening infection with multiresistantStaphylococcus epidermidis in a patient with end-stage renal disease: Cure with chloramphenicol and quinupristin/dalfopristin (RP 59500)

Infection ◽  
1997 ◽  
Vol 25 (4) ◽  
pp. 252-254 ◽  
Author(s):  
E. Mündlein ◽  
H. von Baum ◽  
H. K. Geiss ◽  
M. Springsklee ◽  
M. Zeier ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis

Sarcoma ◽  
2009 ◽  
Vol 2009 ◽  
pp. 1-5 ◽  
Author(s):  
Sheron Latcha ◽  
Robert G. Maki ◽  
Gary K. Schwartz ◽  
Carlos D. Flombaum
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Response To Therapy ◽  
Common Side Effect ◽  
Pharmacokinetic Data ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage ◽  
Metastatic Sarcoma ◽  
Radiographic Improvement

Background. Pharmacokinetic data on clearance of ifosfamide in hemodialysis patients are limited. Consequently, these patients are excluded from therapy with this agent. We review the outcomes for patients at our institution with end stage renal disease on dialysis who received ifosfamide for metastatic sarcoma.Patients and Methods. We treated three patients with end stage renal disease on hemodialysis with escalating doses of ifosfamide. Data on radiographic response to therapy, WBC and platelet counts, signs or symptoms of infection, neuropathy and bladder toxicity are reported. Starting doses of ifosfamide were based on review of the literature available with subsequent modifications based on each patient's prior exposure to myelosuppressive agents and on symptoms of neurotoxicity and the degree of myelosuppression following each cycle of chemotherapy.Results. Myelosuppression was the most common side effect from therapy, but no patient developed a life threatening infection, neurotoxicity, or hematuria. One patient developed epistaxis in the setting of thrombocytopenia while on warfarin therapy. All patients had clinical evidence for therapeutic response and two had documented radiographic improvement following ifosfamide administration.Conclusion. Ifosfamide can be used safely in combination with hemodialysis in patients with end stage renal disease.

Hemorrhage as a life-threatening complication after valve replacement in end-stage renal disease patients

2015 ◽  
Vol 63 (7) ◽  
pp. 386-394 ◽  
Author(s):  
Taro Nakatsu ◽  
Nobushige Tamura ◽  
Shigeki Yanagi ◽  
Shoichi Kyo ◽  
Takaaki Koshiji ◽  
...  
Keyword(s):  
Renal Disease ◽  
Valve Replacement ◽  
End Stage Renal Disease ◽  
Life Threatening ◽  
Life Threatening Complication ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Vancomycin Induced Thrombocytopenia – Protracted Course in a Hemodialysis Patient

2019 ◽  
Vol 12 (3) ◽  
pp. 749-754 ◽  
Author(s):  
Nisha Elizabeth Ajit ◽  
Sindhu Priya Devarashetty ◽  
Samip Master
Keyword(s):  
Renal Disease ◽  
Renal Clearance ◽  
End Stage Renal Disease ◽  
Side Effect ◽  
Hemodialysis Patient ◽  
Treatment Modalities ◽  
Platelet Destruction ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

Vancomycin induced thrombocytopenia (VIT) is an uncommon side effect of vancomycin which can manifest from mild petechiae to life-threatening bleed. Decreased renal clearance of vancomycin results in prolonged thrombocytopenia by antibody-mediated platelet destruction in the presence of vancomycin. Improvement in thrombocytopenia is achieved with the elimination of vancomycin. We describe a patient with end stage renal disease who experienced a protracted course of thrombocytopenia from vancomycin. We illustrate the mechanism of thrombocytopenia and the treatment modalities used by us and those described in literature. VIT is an important differential in patients with thrombocytopenia admitted to the hospital.

Cutaneous manifestations of end-stage renal disease

2015 ◽  
Author(s):  
Timur A. Galperin ◽  
Kieron S. Leslie ◽  
Antonia J. Cronin
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Skin Diseases ◽  
Treatment Options ◽  
Electrolyte Imbalance ◽  
Cutaneous Manifestations ◽  
Metastatic Calcification ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

A broad range of skin diseases occur in patients with end-stage renal disease. Some of these conditions are benign, and make little impact on patients’ lives. Others, however, have a greater impact on quality of life, may be physically disabling, and even life-threatening. Mostly, they result from a combination of factors, such as electrolyte imbalance and co-morbid disease. Uraemic pruritus is the most commonly troublesome and an approach to it is presented. Other non-specific skin manifestations of CKD include skin-colour changes, xerosis, half-and-half nails Specific manifestations include acquired perforating dermatosis, bullous dermatoses, metastatic calcification, and nephrogenic systemic fibrosis. Pathophysiology, clinical presentation, diagnosis, and treatment options are discussed.

scholarly journals Hyperkalemic Recurrent Bilateral Lower Extremity Weakness in a Patient on Hemodialysis

2012 ◽  
Vol 2012 ◽  
pp. 1-3
Author(s):  
Getaw Worku Hassen ◽  
Suzanne Newstead ◽  
Lorraine Maria Giordano
Keyword(s):  
Lower Extremity ◽  
Renal Disease ◽  
Neurological Deficit ◽  
End Stage Renal Disease ◽  
Focal Neurological Deficit ◽  
Lower Extremity Weakness ◽  
Electrolyte Disorder ◽  
Life Threatening ◽  
Stage Renal Disease ◽  
End Stage

Hyperkalemia is a severe life-threatening electrolyte disorder that commonly affects the cardiac conductivity and contractility. Ascending paralysis affecting the extremities with focal neurological deficit as well as quadriparesis and a seizure associated with hyperkalemia has been reported in the literature. Here, we describe a case of isolated recurrent lower extremity paralysis and an episode of seizure in an 83-year-old patient with end-stage renal disease on hemodialysis.

Sign in / Sign up

Export Citation Format

Share Document